36 results on '"Andersson, Michael"'
Search Results
2. Chemotherapy for post‐menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function.
- Author
-
Marina, Djordje, Buch‐Larsen, Kristian, Gillberg, Linn, Andersen, Mads Albrecht, Andersson, Michael, Rasmussen, Åse Krogh, and Schwarz, Peter
- Subjects
ADJUVANT chemotherapy ,BREAST cancer ,AUTOIMMUNE thyroiditis ,RADIATION doses ,CANCER chemotherapy - Abstract
Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer (EBC). Among others, weight gain is one of the observed side effects of both chemotherapy and other cancer treatments; however, the mechanism is not well‐described. In this study, we aimed to assess thyroid function before and shortly after the course of chemotherapy for EBC. Methods: This is a prospective cohort study of women diagnosed with EBC. The main outcome was the thyroid function and body weight before and after completing chemotherapy. Secondary outcomes were the presence of thyroid autoantibodies and treatment radiation dosage. We included 72 patients treated with adjuvant chemotherapy, whereas 59 patients also received supraclavicular locoregional radiotherapy. Triple‐negative breast cancer (BC) patients receiving chemoimmunotherapy were excluded. Results: After the chemotherapy, we observed an increase in thyroid‐stimulating hormone (p = 0.03) and a decrease in free‐thyroxine (p = 0.0006), with no significant weight change. The prevalence of autoimmune thyroiditis was low. On average 3 months post‐chemo, we found no statistically significant difference in the thyroid function of women treated versus not treated with supraclavicular locoregional radiotherapy. Conclusions: Although statistically significant changes in thyroid hormones were observed, this study suggests no obvious clinically significant changes in thyroid function in women with early BC after the course of chemotherapy. The decrease in thyroid function was not related to autoimmunity, non‐thyroidal illness, radiotherapy, or high‐dose corticosteroids. Further studies with a longer follow‐up of thyroid function after adjuvant chemotherapy and supraclavicular locoregional radiotherapy are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Patterns in detection of recurrence among patients treated for breast cancer
- Author
-
Saltbæk, Lena, Horsboel, Trine Allerslev, Offersen, Birgitte Vrou, Andersson, Michael, Friberg, Anne Sofie, Skriver, Signe Korsgaard, Bidstrup, Pernille Envold, Overgaard, Jens, Johansen, Christoffer, and Dalton, Susanne Oksbjerg
- Published
- 2020
- Full Text
- View/download PDF
4. Cardiovascular disease in women with breast cancer – a nationwide cohort study
- Author
-
Jakobsen, Marie, Kolodziejczyk, Christophe, Jensen, Morten Sall, Poulsen, Peter Bo, Khan, Humma, Kümler, Thomas, and Andersson, Michael
- Published
- 2021
- Full Text
- View/download PDF
5. Dose to the Contralateral Breast From Radiotherapy and Risk of Second Primary Breast Cancer in the WECARE Study
- Author
-
Stovall, Marilyn, Smith, Susan A, Langholz, Bryan M, Boice, John D, Shore, Roy E, Andersson, Michael, Buchholz, Thomas A, Capanu, Marinela, Bernstein, Leslie, Lynch, Charles F, Malone, Kathleen E, Anton-Culver, Hoda, Haile, Robert W, Rosenstein, Barry S, Reiner, Anne S, Thomas, Duncan C, Bernstein, Jonine L, and Group, WECARE Study Collaborative
- Subjects
Clinical Research ,Breast Cancer ,Cancer ,7.3 Management and decision making ,Management of diseases and conditions ,Adult ,Body Burden ,Breast Neoplasms ,Denmark ,Female ,Humans ,Incidence ,Middle Aged ,Neoplasms ,Radiation-Induced ,Neoplasms ,Second Primary ,Radiotherapy ,Radiotherapy Dosage ,Relative Biological Effectiveness ,Risk Assessment ,Risk Factors ,Treatment Outcome ,United States ,Women's Health ,Contralateral breast ,Radiation risk ,Secondary breast cancer ,Women's Environmental ,Cancer ,and Radiation Epidemiology Study Collaborative Group ,Other Physical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeTo quantify the risk of second primary breast cancer in the contralateral breast (CB) after radiotherapy (RT) for first breast cancer.Methods and materialsThe study population included participants in the Women's Environmental, Cancer, and Radiation Epidemiology study: 708 cases (women with asynchronous bilateral breast cancer) and 1399 controls (women with unilateral breast cancer) counter-matched on radiation treatment. Participants were 1.0 Gy of absorbed dose to the specific quadrant of the CB had a 2.5-fold greater risk for CB cancer than unexposed women (RR = 2.5, 95% CI 1.4-4.5). No excess risk was observed in women >40 years of age. Women 5 years had a RR of 3.0 (95% CI 1.1-8.1), and the dose response was significant (excess RR per Gy of 1.0, 95% CI 0.1-3.0).ConclusionsWomen 1.0 Gy to the CB had an elevated, long-term risk of developing a second primary CB cancer. The risk is inversely related to age at exposure and is dose dependent.
- Published
- 2008
6. Peripheral blood mononuclear cells exhibit increased mitochondrial respiration after adjuvant chemo‐ and radiotherapy for early breast cancer.
- Author
-
Christensen, Ida Bager, Abrahamsen, Marie‐Louise, Ribas, Lucas, Buch‐Larsen, Kristian, Marina, Djordje, Andersson, Michael, Larsen, Steen, Schwarz, Peter, Dela, Flemming, and Gillberg, Linn
- Subjects
MONONUCLEAR leukocytes ,OXYGEN consumption ,RESPIRATION ,MITOCHONDRIA ,BREAST cancer ,MITOCHONDRIAL DNA - Abstract
Background: Adjuvant chemo‐ and radiotherapy cause cellular damage to tumorous and healthy dividing cells. Chemotherapy has been shown to cause mitochondrial respiratory dysfunction in non‐tumorous tissues, but the effects on human peripheral blood mononuclear cells (PBMCs) remain unknown. Aim: We aimed to investigate mitochondrial respiration of PBMCs before and after adjuvant chemo‐ and radiotherapy in postmenopausal patients with early breast cancer (EBC) and relate these to metabolic parameters of the patients. Methods: Twenty‐three postmenopausal women diagnosed with EBC were examined before and shortly after chemotherapy with (n = 18) or without (n = 5) radiotherapy. Respiration (O2 flux per million PBMCs) was assessed by high‐resolution respirometry of intact and permeabilized PBMCs. Clinical metabolic characteristics and mitochondrial DNA (mtDNA) content of PBMCs (mtDN relative to nuclear DNA) were furthermore assessed. Results: Respiration of intact and permeabilized PBMCs from EBC patients significantly increased with adjuvant chemo‐ and radiotherapy (p = 6 × 10−5 and p = 1 × 10−7, respectively). The oxygen flux attributed to specific mitochondrial complexes and respiratory states increased by 17–43% compared to before therapy initiation. Similarly, PBMC mtDNA content increased by 40% (p = 0.002). Leukocytes (p = 0.0001), hemoglobin (p = 0.0003), and HDL cholesterol (p = 0.003) concentrations decreased whereas triglyceride (p = 0.01) and LDL (p = 0.02) concentrations increased after treatment suggesting a worsened metabolic state. None of the metabolic parameters or the mtDNA content of PBMCs correlated significantly with PBMC respiration. Conclusion: This study shows that mitochondrial respiration and mtDNA content in circulating PBMCs increase after adjuvant chemo‐ and radiotherapy in postmenopausal patients with EBC. Besides the increased mtDNA content, a shift in PBMC subpopulation proportions towards cells relying on oxidative phosphorylation, who may be less sensitive to chemotherapy, might influence the increased mitochondrial respiration observed iafter chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study
- Author
-
Praestegaard, Camilla, Kjaer, Susanne K., Andersson, Michael, Steding-Jensen, Marianne, Frederiksen, Kirsten, and Mellemkjaer, Lene
- Published
- 2016
- Full Text
- View/download PDF
8. Real-world survival of Danish patients with HER2-positive metastatic breast cancer.
- Author
-
Artzi, Daniel, Berg, Tobias, Celik, Alan, Kümler, Iben, Kenholm, Julia, Al-Rawi, Sami, Jensen, Maj-Britt, Andersson, Michael, and Knoop, Ann
- Subjects
BREAST cancer prognosis ,BREAST tumor diagnosis ,THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of antineoplastic agents ,BRAIN ,PATIENT aftercare ,CONFIDENCE intervals ,ONCOGENES ,TRASTUZUMAB ,METASTASIS ,MEDICAL protocols ,CANCER patients ,ESTROGEN receptors ,KAPLAN-Meier estimator ,RESEARCH funding ,TUMOR markers ,PROGRESSION-free survival ,VINORELBINE ,BREAST tumors ,OVERALL survival - Abstract
The purpose was to investigate the treatment flow of patients with HER2-positive metastatic breast cancer (mBC), progression-free survival (PFS) and overall survival (OS) across treatment lines and adherence to guidelines (defined as trastuzumab, pertuzumab and chemotherapy first line, where 85% received vinorelbine as backbone and T-DM1 second line). Furthermore, we identified clinical markers to predict the risk of developing brain metastases. Patients with HER2-positive mBC, diagnosed between 01.01.2014–31.12.2019, registered in the database of the Danish Breast Cancer Group were included in this real-word study. Clinical follow-up was assessed until 01.10.2020 and complete follow-up for overall survival until 01.10.2021. Survival data were analyzed using the Kaplan-Meier method with guidelines adherence analyzed as a time-varying covariate, and the risk of CNS metastasis was estimated by the cumulative incidence function. 631 patients were included. 329 (52%) patients followed the guidelines. The median OS for all patients was 42.3 months (95% Cl, 38.2–48.4), and significantly higher for the patients who followed guidelines; NA (95% CI, 78.2–NA). The median PFS for all patients was 13.4 months (95% Cl, 12.1–14.8), 6.6 (95% Cl, 5.8–7.6) and 5.8 (95% Cl, 4.9–6.9) for first, second and third line of treatment, respectively. Patients with ER-negative mBC had a higher risk of developing brain metastases and patients with high tumor burden had a higher risk of developing brain metastases with an adjusted HR of 0.69 (95% CI, 0.49–0.98), p = 0.047 and 2.69 (95% CI, 1.45–5.00), p = 0.002, respectively. We found that only half of the patients with HER2-positive mBC, received first and second-line treatment according to national guidelines. Patients receiving treatment according to guidelines had a significantly higher median OS compared to patients who did not. We also found that patients with ER-negative disease or high tumor burden had a significantly higher risk of developing brain metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
- Author
-
Marina, Djordje, Rasmussen, Åse Krogh, Buch‐Larsen, Kristian, Gillberg, Linn, Andersson, Michael, and Schwarz, Peter
- Subjects
METASTATIC breast cancer ,THYROID diseases ,TAMOXIFEN ,LETROZOLE ,THYROID gland ,WEIGHT gain - Abstract
Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti‐oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. While the most common side‐effects of this therapy are well‐defined, less is known about its effects on thyroid function. In women treated for early BC, an average of 1–5 kg weight gain has been observed after treatment with chemotherapy/anti‐oestrogens. We aim to evaluate the current knowledge on the side effects of tamoxifen and letrozole treatments on thyroid function, followed by its potential influence on the observed weight gain. Methods: We searched PubMed and found 16 publications on thyroid function and tamoxifen treatment in pre‐ and post‐menopausal women with early‐ and advanced BC, whereas five publications on letrozole treatment in post‐menopausal women with advanced BC. Results: According to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen‐treated patients. Only one publication reported further significant changes in thyroid hormones beyond one year of tamoxifen treatment. No significant changes in thyroid function have been observed among letrozole‐treated patients. Conclusion: Tamoxifen‐treated patients can develop mild and transient thyroid dysfunction within the first 12 months, yet further significant changes in thyroid function beyond one year of tamoxifen treatment have been reported in a single study. There is no evidence of thyroid dysfunction in letrozole‐treated patients. Current literature does not focus on subclinical hypothyroidism as a possible cause of weight gain in patients with BC. Subgrouping of BC patients and studies with a longer observation of thyroid hormones and weight changes during and after anti‐oestrogen treatment are needed to further elucidate how anti‐oestrogens affect thyroid function. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Risk of breast cancer in Danish women occupationally exposed to organic solvents, including ethanol.
- Author
-
Pedersen, Julie Elbaek, Strandberg‐Larsen, Katrine, Andersson, Michael, and Hansen, Johnni
- Subjects
BREAST cancer ,ORGANIC solvents ,DISEASE risk factors ,ORGANIC farmers ,OCCUPATIONAL exposure ,ESTROGEN receptors - Abstract
Background: Organic solvents have been suggested to increase the risk of breast cancer although the epidemiologic evidence is limited. This study explored the association between organic solvents and breast cancer. Methods: This nested population‐based case‐control study comprised 845 women with primary breast cancer initially identified in the Danish Cancer Registry between 2000 and 2003, and 1500 controls matched on year of birth who were randomly selected from the Danish Civil Registration System. Information on occupational exposure to organic solvents, and specifically ethanol, as well as risk factors for breast cancer was collected through structured interviews. Results: For organic solvents, an increased risk was indicated for ever‐exposure (odds ratio = 3.20, 95% confidence interval: 2.27–4.52), however, no noteworthy risk patterns were detected when exploring duration of exposure and cumulative exposure. Ever‐exposure to organic solvents was associated with an increased risk of estrogen receptor negative and positive tumors as well as pre‐ and postmenopausal breast cancer. No associations were detected between occupational exposure to ethanol and breast cancer. Conclusions: This study indicates a positive association between organic solvents and breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Supraclavicular recurrence after early breast cancer: a curable condition?
- Author
-
Pedersen, Anders N., Møller, Susanne, Steffensen, Karina D., Haahr, Vera, Jensen, Merete, Kempel, Mette M., Jepsen, Søren L., Madsen, Ebbe L., Roslind, Anne, Sandberg, Erik, Schöllkopf, Claudia, Sørensen, Peter G., Windfeldt, Karen Margrethe, and Andersson, Michael
- Published
- 2011
- Full Text
- View/download PDF
12. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
- Author
-
de Azambuja, Evandro, McCaskill-Stevens, Worta, Francis, Prudence, Quinaux, Emmanuel, Crown, John P. A., Vicente, Malou, Giuliani, Rosa, Nordenskjöld, Bo, Gutiérez, Jorge, Andersson, Michael, Vila, Mireia Margeli, Jakesz, Raimund, Demol, Jan, Dewar, Joanna, Santoro, Armando, Lluch, Ana, Olsen, Steven, Gelber, Richard D., Di Leo, Angelo, and Piccart-Gebhart, Martine
- Published
- 2010
- Full Text
- View/download PDF
13. Risk of second non-hematological malignancies among 376,825 breast cancer survivors
- Author
-
Brown, Linda Morris, Chen, Bingshu E., Pfeiffer, Ruth M., Schairer, Catherine, Hall, Per, Storm, Hans, Pukkala, Eero, Langmark, Frøydis, Kaijser, Magnus, Andersson, Michael, Joensuu, Heikki, Fosså, Sophie D., and Travis, Lois B.
- Published
- 2007
- Full Text
- View/download PDF
14. Leukemia following breast cancer: an international population-based study of 376,825 women
- Author
-
Howard, Regan A., Gilbert, Ethel S., Chen, Bingshu E., Hall, Per, Storm, Hans, Pukkala, Eero, Langmark, Froydis, Kaijser, Magnus, Andersson, Michael, Joensuu, Heikki, Fossa, Sophie D., and Travis, Lois B.
- Published
- 2007
- Full Text
- View/download PDF
15. Mortality from cardiovascular disease in women with breast cancer – a nationwide registry study.
- Author
-
Kolodziejczyk, Christophe, Jakobsen, Marie, Sall Jensen, Morten, Poulsen, Peter Bo, Khan, Humma, Kümler, Thomas, and Andersson, Michael
- Subjects
CARDIOVASCULAR disease related mortality ,CAUSES of death ,MULTIVARIATE analysis ,REGRESSION analysis ,CASE-control method ,RISK assessment ,CANCER patients ,DESCRIPTIVE statistics ,BREAST tumors ,WOMEN'S health ,PROPORTIONAL hazards models - Abstract
Only few existing studies have investigated the mortality from cardiovascular disease (CVD) in women with breast cancer (BC). The aim of this study was to investigate CVD mortality in patients with BC compared with a matched control group without BC using national registry data. We followed 16,505 Danish women diagnosed with BC in 2003–2007 up to 10 years after BC diagnosis compared with 165,042 matched controls from the general Danish population. The matching criteria included gender, age, region of residence, and education. We performed multivariate Cox regression analyses to investigate the influence of preexisting CVD on mortality. Moreover, we used the cumulative incidence and conditional probability functions to study the risk of CVD-related death in the presence of competing risk, i.e., the risk of dying from other causes than CVD. We found that preexisting CVD increased both overall mortality and CVD mortality in both patients with BC and controls. Furthermore, we found that patients with BC were at lower risk of dying from CVD up to 10 years after BC diagnosis compared with controls. The cumulative incidence of CVD as underlying cause of death was 4.0% in patients with BC and 5.7% in controls after 10 years. The most common CVD-related causes of death were ischemic heart disease including acute coronary syndrome, cerebrovascular accident, heart failure, and atrial fibrillation. Our study contributes to the growing body of work on BC and comorbidities and highlights the importance of CVD in individuals with BC. Further studies are needed to confirm our finding that patients with BC are at lower risk of dying from CVD up to 10 years after BC diagnosis compared with a matched control group without BC [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.
- Author
-
Buch-Larsen, Kristian, Jørgensen, Niklas Rye, Jensen, Lars Thorbjørn, Andersson, Michael, and Schwarz, Peter
- Subjects
BREAST cancer ,AROMATASE inhibitors ,MENOPAUSE ,DENOSUMAB ,ZOLEDRONIC acid - Abstract
Adjuvant treatment for post-menopausal women with early breast cancer (BC) includes aromatase inhibitors (AI), known to decrease bone mineral density (BMD). In this study, we investigate whether denosumab is a valid second option for patients unable to receive standard adjuvant i.v. zoledronic acid (ZA). In total, 212 patients have been evaluated after they did not receive ZA. Of those 194 were included. After evaluation by an endocrinologist, all patients were offered ZA as their first choice and 15% accepted (N = 29). The remaining 85% were offered denosumab (N = 165). All patients were followed prospectively with blood tests up to 24 months. DXA scans were performed at baseline and 24 months. No difference was observed between the two treatment groups at baseline, with regard to anthropometry and standard biochemistry. Markers of bone turnover (p-PINP, p-CTX, p-bone-specific alkaline phosphatase and p-osteocalcin) all showed significant suppression compared to baseline and remained suppressed throughout the 2 years. BMD showed small and significant increases at the spine (0.024 g/cm
2 ) and total hip (0.019 g/cm2 ) in the denosumab group but no change at the femoral neck(–0.011g/cm2 ). In the ZA group, we observed no significant change at the spine (0.015 g/cm2 ) and total hip (–0.001g/cm2 ) and a small significant decrease at the femoral neck (–0.037 g/cm2 ). However, when we compared BMD change between the treatment groups, we found no significant difference. Conclusions: Our data indicate that for BC patients in AI treatment who refused or were not able to receive ZA treatment, denosumab might be recommended as a second choice. Regarding markers of bone turnover and BMD denosumab is equal to ZA. Summary: Women with early breast cancer receiving anti-estrogen treatment are at risk of developing osteoporosis. We followed 194 women receiving zoledronic acid (ZA) or denosumab for up to 2 years. We find that with regard to bone protection, denosumab is a viable alternative to ZA and might be recommended as a second choice [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Breast cancer among Danish women occupationally exposed to diesel exhaust and polycyclic aromatic hydrocarbons, 1964-2016.
- Author
-
Pedersen, Julie Elbæk, Strandberg-Larsen, Katrine, Andersson, Michael, and Hansen, Johnni
- Subjects
POLYCYCLIC aromatic hydrocarbons ,BREAST cancer ,OCCUPATIONAL exposure ,ESTROGEN receptors ,BREAST tumors - Abstract
Objective The aim of this study was to explore the association between occupational exposure to diesel exhaust and polycyclic aromatic hydrocarbons (PAH), respectively, and breast cancer subtypes. Methods The study included 38 375 women <70 years with incident breast cancer, identified in the Danish Cancer Registry, and 5 breast cancer-free controls per case who were randomly selected from the Danish Civil Registration System and matched on year of birth. Full employment history was obtained for all study subjects from a nationwide pension fund, and exposure to diesel exhaust and PAH was assessed using a job exposure matrix. Conditional logistic regression was used for estimation of odds ratios (OR) with adjustment for reproductive factors and socioeconomic status. Results No noteworthy associations were observed for overall breast cancer in women exposed to diesel exhaust. However, diesel exhaust modestly elevated the risk of estrogen receptor negative breast tumors before age 50 [OR 1.26, 95% confidence interval (CI) 1.09-1.46]. Duration- and dose-response relationships were further observed for this subtype in this age group. No notable risk patterns were generally observed for PAH exposure. Conclusion Occupational exposure to diesel exhaust may increase the risk of early-onset estrogen receptor negative breast tumors in women. Future studies exploring this association are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
- Author
-
Berg, Tobias, Jensen, Maj-Britt, Jakobsen, Erik H., Al-Rawi, Sami, Kenholm, Julia, and Andersson, Michael
- Subjects
NEOADJUVANT chemotherapy ,TRASTUZUMAB ,BREAST cancer ,ESTROGEN receptors - Abstract
Dual blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy (NACT) has been increasingly used for HER2-positive tumours >2 cm and/or with positive axillary lymph nodes in order to evaluate pathologic response and obtain better surgical management. SB3 is a registered biosimilar trastuzumab approved following a phase III trial demonstrating similar efficacy in the neoadjuvant setting as trastuzumab. However, the study was done without pertuzumab. The database of the Danish Breast Cancer Group was used to extract data on all patients who started NACT with SB3 and pertuzumab between September 1, 2018 and August 31, 2019. The primary endpoint was pathological complete response (pCR) rate. In total 215 patients received NACT and dual blockade. The median age was 55 (24–81). NACT used was cyclophosphamide and epirubicin followed by weekly paclitaxel (62% on six cycles, 35% on eight cycles) or other chemotherapy followed by weekly paclitaxel (3%). Overall, 56% of patients achieved pCR. 60 of 88 node-positive patients pre-NACT achieved ypN0(i-) after neoadjuvant treatment. pCR rate was significantly associated with estrogen receptor status and malignancy grade. An association with CEP17/HER2-ratio was assessed. Real world data on dual blockade with SB3 and pertuzumab in combination with NACT in a nationwide population-based study show a pCR rate comparable to that seen in previous clinical studies. • Real world data on 215 patients with HER2-positive early breast cancer. • SB3 (biosimilar trastuzumab) and pertuzumab with neoadjuvant chemotherapy. • pCR in 56% and node conversion in 68% of the patients. • pCR rate associated with ER-status and malignancy grade. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review.
- Author
-
Buch, Kristian, Gunmalm, Victoria, Andersson, Michael, Schwarz, Peter, and Brøns, Charlotte
- Subjects
THERAPEUTICS ,ADJUVANT treatment of cancer ,AROMATASE inhibitors ,META-analysis - Abstract
Introduction: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. Methods: We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. Results: A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Discussion: Due to methodological limitations including short follow‐up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high‐risk of developing cardiometabolic disease after BC treatment. A systematic review on the changes in metabolism caused by adjuvant chemotherapy and/or aromatase inhibitors in the treatment of breast cancer (BC). We find a trend of increase in glucose and insulin. This could potentially lead to increased risk of cardiometabolic disease of BC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Mortality after contralateral breast cancer in Denmark.
- Author
-
Langballe, Rikke, Frederiksen, Kirsten, Jensen, Maj-Britt, Andersson, Michael, Cronin-Fenton, Deirdre, Ejlertsen, Bent, and Mellemkjær, Lene
- Abstract
Purpose: How a second breast cancer diagnosis affects survival in comparison with unilateral breast cancer (UBC) is unclear. Prognostic factors for contralateral breast cancer (CBC) are also not well established. We aimed to investigate the survival pattern after CBC with particular focus on time between first and second breast cancer diagnosis and age at CBC diagnosis.Methods: Within the nationwide Danish Breast Cancer Cooperative Group database, we identified 68,466 breast cancer patients diagnosed during 1978-2012. Patients who subsequently developed CBC were identified in a previously established database (N = 3004). Patients were followed for breast cancer-specific death in the Danish Register of Causes of Death until 2015. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard regression models. Cumulative breast cancer mortality from date of CBC was estimated using the Aalen-Johansen method.Results: Compared with UBC patients, the rate of dying from breast cancer was more than twofold higher following a CBC diagnosis, after adjustment for age, period, tumor characteristics, and treatment of the first breast cancer (HR 2.48; 95% CI 2.31-2.66). Short time interval (< 5 years) was associated with higher breast cancer-specific mortality after CBC among patients < 70 years at CBC diagnosis compared with longer time intervals, but not among patients ≥ 70 years at CBC diagnosis.Conclusion: Breast cancer-specific mortality rates were markedly higher after compared with before a CBC diagnosis. We found higher breast cancer-specific mortality after CBC associated with a short interval between diagnoses among patients diagnosed with CBC before age 70 years. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Checkpoint inhibitors in breast cancer - Current status.
- Author
-
Polk, Anne, Svane, Inge-Marie, Andersson, Michael, and Nielsen, Dorte
- Abstract
Introduction: An increasing number of compounds directed against immune checkpoints are currently under clinical development. In this review we summarize current research in breast cancer.Material and Methods: A computer-based literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well.Results: The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to 30% in heavily pretreated triple negative breast cancer (TNBC). The median duration of progression free survival and overall survival were either not reported or short. Still responses were of long duration in a subset of patients. In the neoadjuvant setting, preliminary results including a very limited number of patients suggest high pathological response rates after combined blockade of the PD-1 pathway and chemotherapy. Multiple trials have been initiated to evaluate the combination of other anticancer agents and checkpoint inhibitors, especially in TNBC. In addition, ongoing studies aim to identify biomarkers to guide patient selection.Conclusion: Immune checkpoint inhibitors have the potential to produce durable tumor remission and induce long standing anti-tumor immunity in a subgroup of breast cancer patients. However, the identification of predictive biomarkers is crucial for further development of this treatment modality. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
- Author
-
Langballe, Rikke, Mellemkjær, Lene, Malone, Kathleen E., Lynch, Charles F., John, Esther M., Knight, Julia A., Bernstein, Leslie, Brooks, Jennifer, Andersson, Michael, Reiner, Anne S., Liang, Xiaolin, Woods, Meghan, Concannon, Patrick J., Bernstein, Jonine L., and WECARE Study Collaborative Group
- Subjects
BREAST cancer risk factors ,BREAST cancer treatment ,CANCER chemotherapy ,MEDICAL records ,TAMOXIFEN ,ANTINEOPLASTIC agents ,BREAST tumors ,PUBLIC health surveillance ,RESEARCH funding ,RISK assessment ,CASE-control method ,SECONDARY primary cancer ,ODDS ratio - Abstract
Background: Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics.Methods: The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985-2008. Abstraction of medical records provided detailed treatment information, while information on risk factors was obtained during telephone interviews. Risk ratios (RRs) and 95 % confidence intervals (CIs) for CBC were obtained from multivariable conditional logistic regression models.Results: Compared with never users of tamoxifen, the RR of CBC was lower for current users of tamoxifen (RR = 0.73; 95 % CI = 0.55-0.97) and for past users within 3 years of last use (RR = 0.73; 95 % CI = 0.53-1.00). There was no evidence of an increased risk of estrogen receptor-negative CBC associated with ever use of tamoxifen or use for 4.5 or more years. Use of chemotherapy (ever versus never use) was associated with a significantly reduced RR of developing CBC 1-4 years (RR = 0.59; 95 % CI = 0.45-0.77) and 5-9 years (RR = 0.73; 95 % CI = 0.56-0.95) after first breast cancer diagnosis. RRs of CBC associated with tamoxifen or with chemotherapy use were independent of age, family history of breast cancer, body mass index and tumor characteristics of the first breast cancer with the exception that the RR of CBC was lower for lobular histology compared with other histologies.Conclusion: Our findings are consistent with previous studies showing that treatment with tamoxifen or chemotherapy is associated with a lower risk of CBC although the risk reduction appears to last for a limited time period after treatment is completed. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
23. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
- Author
-
Nielsen, Dorte L., Kümler, Iben, Palshof, Jesper A.E., and Andersson, Michael
- Subjects
BREAST cancer treatment ,HER2 gene ,DRUG efficacy ,MONOCLONAL antibodies ,PROTEIN-tyrosine kinase inhibitors ,TRASTUZUMAB ,ADENOSINE monophosphate - Abstract
Abstract: Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in metastatic breast cancer (MBC). We review the efficacy of HER2-directed therapies, focussing on monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 that have been tested in phase II–III studies in MBC. Trastuzumab is an important component of first-line treatment of HER2-positive MBC. New anti-HER2 drugs have the potential to change clinical practice. The potential role of the different drugs and regimens is yet to be determined. The response rate for trastuzumab-DM1 of 26–64% is comparable to those obtained for capecitabine plus lapatinib (48%), continuing trastuzumab in combination with capecitabine (48%), pertuzumab plus trastuzumab (24%), and neratinib (24%). Strategies combining multiple HER2-directed therapies might yield additive or synergistic effects and lead to improved outcome. The future challenges include understanding HER2 functions, designing rational combinations and optimal selection of patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
24. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
- Author
-
Azambuja, Evandro, McCaskill-Stevens, Worta, Francis, Prudence, Quinaux, Emmanuel, Crown, John, Vicente, Malou, Giuliani, Rosa, Nordenskjöld, Bo, Gutiérez, Jorge, Andersson, Michael, Vila, Mireia, Jakesz, Raimund, Demol, Jan, Dewar, Joanna, Santoro, Armando, Lluch, Ana, Olsen, Steven, Gelber, Richard, Di Leo, Angelo, and Piccart-Gebhart, Martine
- Abstract
Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m². Results: In total, 547 (19%) patients were obese at baseline, while 2,340 (81%) patients were non-obese. Estimated 5-year OS was 87.5% for non-obese and 82.9% for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9% for non-obese and 70.0% for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
- Author
-
Nielsen, Dorte Lisbet, Andersson, Michael, and Kamby, Claus
- Abstract
Summary: There is strong clinical evidence that trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important component of first-line treatment of patients with HER2-positive metastatic breast cancer. In particular the combination with taxanes and vinorelbine has been established. In the preoperative setting inclusion of trastuzumab has significantly increased the pathological complete response rate. Results from large phase III trials evaluating adjuvant therapy in HER2-positive early breast cancer indicate that the addition of trastuzumab to chemotherapy improves disease-free and overall survival. The use of lapatinib, a dual tyrosine kinase inhibitor of both HER1 and HER2, in combination with capecitabine in the second-line treatment of HER2-positive patients with metastatic breast cancer previously treated with trastuzumab has been established. There is modest, but still insufficient, support that the compound passes the blood-brain barrier. Several trials are ongoing both in the adjuvant and metastatic settings and we have to await the results of these to clarify the role of trastuzumab and lapatinib. The clinical problem of tumours developing resistance to HER2-directed therapy is becoming increasingly important. Several issues about optimal selection of patients, prevention of resistance and use of different treatment options are still unresolved. In this article, we summarise the current knowledge on clinical evidence of HER2-directed therapy and the potential mechanisms of underlying resistance, including the possible clinical implications and review new therapeutic options. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
26. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001.
- Author
-
Andersson, Michael, Jensen, Maj-Britt, Engholm, Gerda, and Storm, Hans Henrik
- Subjects
- *
BREAST cancer , *CANCER treatment , *COOPERATIVE societies , *ANTINEOPLASTIC agents , *LUNG cancer - Abstract
Breast cancer survivors have increased risks of developing second primary cancers due to shared etiology, life style factors but also to primary breast cancer treatment. Among 53 418 patients registered by the population based Danish Breast Cancer Cooperative Group (DBCG) during 1977-2001, 31 818 patients were treated and followed according to guidelines of DBCG. In addition to surgery 23% received tamoxifen, 23% chemotherapy and 35% radiotherapy as treatment for primary breast cancer. Second primary cancers were identified by linkage to the population based Danish Cancer Register. Cancer incidence rates of the Danish population were used for calculation of standardized incidence ratios (SIRs). Time at risk was from diagnosis of breast cancer+1 year until death or through 2002. Risk for all second primary cancers combined was increased, SIR=1.04 (95% confidence interval 0.99-1.08). Sites with significantly elevated risks included corpus uteri (SIR=1.23), ovary (1.39), soft tissues (2.24), acute leukaemia (2.02), and sites potentially inducible by breast cancer radiotherapy combined (1.11). For irradiated patients compared to non-irradiated the risk was increased for all sited combined, radiotherapy-related sites, colon and soft tissues. Tamoxifen treated had, compared to non-treated, elevated risk for cancer of corpus uteri (SIR=1.83 vs 1.04). Patients given adjuvant chemotherapy had, compared to those not, elevated risks for all sites combined (SIR=1.24 vs 1.01) and for ovary (2.16 vs 1.24). Risk for cancer of the lung, uterus and ovary was analysed using multivariate Poisson regression. For lung cancer the risk was related to radiotherapy and time since diagnosis, the relative risk for lung cancer being 1.33 (95% CI 1.00-1.77) (irradiated vs non-irradiated). Ovary cancer risk was inversely related to age at diagnosis but not to treatment and corpus uteri cancer risk related to tamoxifen treatment, relative risk 1.57. The findings are in accordance to other population based studies. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
27. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables
- Author
-
Bruun Rasmussen, Birgitte, Andersson, Michael, Christensen, Ib J., and Møller, Susanne
- Subjects
- *
BREAST cancer , *HER2 gene , *ASSOCIATIONS, institutions, etc. , *PATHOLOGICAL laboratories , *MONOCLONAL antibodies - Abstract
Introduction. In Denmark, analysis for HER2 is situated in the pathology laboratories dealing with breast pathology. The analysis was introduced during the late 1990's, and was gradually intensified in the following years up to now. The present study deals with the experience with the analysis during the last 5 years, from 2002 - 2006. Patients and methods. All patients, registered in DBCG (Danish Breast Cancer Group) and with a HER2-test were included. The analysis followed international recommendations, with an initial immunohistochemical (IHC) analysis with a semiquantitative grading of the reaction in four grades, 0 and 1+, defined as HER2-negative, 2+, equivocal and 3+, HER2-positive. In the 2+ group, a FISH-test was applied to identify the presence of gene amplification, defined as a ratio ≥2. We investigated the number of analyses performed, the number of positive cases and the relation between the result of IHC and the result of FISH. Furthermore we looked at the relation to other prognostic factors. Results. The number of analyses gradually increased during the years of investigation, from 30% of patients in 2002 to 71% in 2006. The increase was seen in all laboratories resulting in all laboratories but one having a substantial number of analyses. Sixty-two percent of all cases were HER2-negative, 18% were equivocal and 21% positive in the IHC-analysis. Of the 2+, equivocal cases, 23% had gene-amplification. Thus, 23% of patients were defined as HER2-positive and eligible for treatment with trastuzumab. There was a significant correlation to other prognostic factors. The results are in accordance with what is found elsewhere. The quality of the test is further assured by all laboratories participating in external quality assurance schemes. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
28. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial.
- Author
-
Francis, Prudence, Crown, John, Di Leo, Angelo, Buyse, Marc, Balil, Ana, Andersson, Michael, Nordenskjöld, Bo, Lang, Istvan, Jakesz, Raimund, Vorobiof, Daniel, Gutiérrez, Jorge, Van Hazel, Guy, Dolci, Stella, Jamin, Sophie, Bendahmane, Belguendouz, Gelber, Richard D., Goldhirsch, Aron, Castiglione-Gertsch, Monica, and Piccart-Gebhart, Martine
- Subjects
IMMUNOLOGICAL adjuvants ,DRUG therapy ,ANTHRACYCLINES ,DOCETAXEL ,BREAST cancer - Abstract
Background: Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel. Methods: Patients with lymph node-positive breast cancer (n = 2887) were randomly assigned to one of four treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m
2 , followed by three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2 , followed by three cycles of CMF); 3) sequential docetaxel (three cycles of doxorubicin at 75 mg/m2 , followed by three cycles of docetaxel at 100 mg/m2 , followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2 , followed by three cycles of CMF). The primary comparison evaluated the efficacy of including docetaxel regardless of schedule and was planned after 1215 disease-free survival (DFS) events (ie, relapse, second primary cancer, or death from any cause). Docetaxel and control treatment groups were compared by log-rank tests, and hazard ratios (HR) of DFS events were calculated by Cox modeling. All statistical tests were two-sided. Results: Due to a lower-than-anticipated rate of relapse, this analysis was performed after 5 years with 732 events. Patients in control arms had a 5-year DFS of 73% (95% confidence interval [Cl] = 70% to 75%). Docetaxel treatment resulted in an improvement in DFS of borderline statistical significance compared with control treatment (HR = 0.86, 95% Cl = 0.74 to 1.00; P = .05). However, DFS in the sequential docetaxel arm was better than that in the concurrent docetaxel arm (HR = 0.83, 95% Cl = 0.69 to 1.00) and in the sequential control arm (HR = 0.79, 95% Cl = 0.64 to 0.98). Conclusions: Incorporating docetaxel into anthracycline-based therapy resulted in an improvement in DFS that was of borderline statistical significance. However, important differences may be related to doxorubicin and docetaxel scheduling, with sequential but not concurrent administration, appearing to produce better DFS than anthracycline-based chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
29. Suicide After Breast Cancer: a International Population-Based Study of 723810 Women.
- Author
-
Schairer, Catherine, Brown, Linda Morris, Chen, Bingshu E., Howard, Regan, Lynch, Charles F., Hall, Per, Storm, Hans, Pukkala, Eero, Anderson, Aage, Kaijser, Magnus, Andersson, Michael, Joensuu, Heikki, Fosså, Sophie D., Ganz, Patricia A., and Travis, Lois B.
- Subjects
SUICIDE ,CANCER patients ,BREAST cancer ,CANCER in women - Abstract
Few studies have examined long-term suicide risk among breast cancer survivors, and there are no data for women in the United States. We quantified suicide risk through 2002 among 723 810 1-year breast cancer survivors diagnosed between January 1, 1953, and December 31, 2001, and reported to 16 population-based cancer registries in the United States and Scandinavia. Among breast cancer survivors, we calculated standardized mortality ratios (SMRs) and excess absolute risks (EARs) compared with the general population, and the probability of suicide. We used Poisson regression likelihood ratio tests to assess heterogeneity in SMRs; all statistical tests were two-sided, with a .05 cutoff for statistical significance. In total 836 breast cancer patients committed suicide (SMR = 1.37, 95% confidence interval IC!] = 1.28 to 1.47; EAR = 4.1 per 100000 person-years). Although SMRs ranged from 1.25 to 1.53 among registries, with 245 deaths among the sample of US women (SMR 1.49, 95% Cl = 1.32 to 1.70), differences among registries were not statistically significant (P for heterogeneity = .19). Risk was elevated throughout follow-up, including for 25 or more years after diagnosis (SMR = 1.35, 95% Cl = 0.82 to 2.12), and was highest among black women (SMR = 2.88, 95% CI = 1.44 to 5.17) (P for heterogeneity = .06). Risk increased with increasing stage of breast cancer (P for heterogeneity .08) and remained elevated among women diagnosed between 1990 and 2001 (SMR = 1.36, 95% Cl = 1.18 to 1.57). The cumulative probability of suicide was 0.20% 30 years after breast cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
30. Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma.
- Author
-
Travis, Lois B., Hill, Deirdre, Dores, Graça M., Gospodarowicz, Mary, Van Leeuwen, Flora E., Holowaty, Eric, Glimelius, Bengt, Andersson, Michael, Pukkala, Eero, Lynch, Charles F., Pee, David, Smith, Susan A., Van't Veer, Mars B., Joensuu, Timo, Storm, Hans, Stovall, Marilyn, Boice Jr., John D., Gilbert, Ethel, and Gail, Mitchell H.
- Subjects
BREAST cancer ,CANCER in women ,HODGKIN'S disease ,CANCER treatment ,CANCER diagnosis ,CANCER-related mortality - Abstract
Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. Methods: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20–«40 Gy, or ≥40 Gy) and use of alkylating agents (yes or no) were estimated from a case-control study conducted within an international population-based cohort of 3817 female 1-year survivors of HL diagnosed at age 30 years or younger from January 1, 1965, through December 31, 1994. To compute cumulative absolute risks of breast cancer, we used modified standardized incidence ratios to relate cohort breast cancer risks to those in the general population, enabling application of population-based breast cancer rates, and we allowed for competing risks by using population-based mortality rates in female HL survivors. Results: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. Conclusions: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
31. Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy—Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort.
- Author
-
Buch-Larsen, Kristian, Lund-Jacobsen, Trine, Andersson, Michael, and Schwarz, Peter
- Abstract
Women with breast cancer are a growing population due to improved screening and treatment. It has been described that chemotherapy can negatively affect patients' metabolism. The aim of this study is to assess weight gain during chemotherapy treatment in an interim analysis on an ongoing prospective cohort of women with early breast cancer. To help untangle the many possible reasons for weight change, we examine blood tests, Patient-Reported Outcomes (PROs), and bone mineral density (BMD). We find that the 38 women that have measurements taken after chemotherapy have an average weight gain of 1.2 kg although not significant. Together with this, there is a significant drop in HDL cholesterol, an increase in triglycerides, and a non-significant tendency towards decreased insulin sensitivity. PROs show that although the women experience more pain and fatigue, they have higher activity levels. BMD is at an expected level according to age. All in all, we see an increased focus on physical activity and nutrition, leading to less severe metabolic changes as previously reported. However, even though more measures are taken, we still see an overall negative metabolic impact with unknown long-term implications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
- Author
-
Goldhirsch, Aron, Gelber, Richard D., Piccart-Gebhart, Martine J., de Azambuja, Evandro, Procter, Marion, Suter, Thomas M., Jackisch, Christian, Cameron, David, Weber, Harald A., Heinzmann, Dominik, Dal Lago, Lissandra, McFadden, Eleanor, Dowsett, Mirth, Untch, Michael, Gianni, Luca, Bell, Richard, Köhne, Claus-Henning, Vindevoghel, Anita, Andersson, Michael, and Brunt, A. Murray
- Subjects
- *
ADJUVANT treatment of cancer , *CANCER treatment , *HER2 gene , *PROTO-oncogenes , *BREAST cancer - Abstract
Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial. Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were disease-free 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of I year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.gov, number NCT00045032. Findings We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0.99, 95% CI 0.85-1.14, p=0.86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group (342 [20.4%] vs 275 [16-3%] grade 3--4 adverse events, and 120 [7-2%] vs 69 [4-1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0.76 (95% CI 0.67-0.86, p<0.0001) for disease-free survival and 0.76 (0.65-0- 88, p=0.0005) for overall survival, despite crossover of 884 (52%) patients from the observation group to trastuzumab therapy. Interpretation 2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer. 1 year of treatment provides a significant disease-free and overall survival benefit compared with observation and remains the standard of care. Funding F Hoffmann-La Roche (Roche). [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
- Author
-
Ejlertsen, Bent, Jensen, Maj-Britt, Elversang, Johanna, Rasmussen, Birgitte B., Andersson, Michael, Andersen, Jørn, Nielsen, Dorte L., Cold, Søren, and Mouridsen, Henning T.
- Subjects
- *
ANTINEOPLASTIC agents , *TAMOXIFEN , *THERAPEUTIC use of biochemical markers , *BREAST tumors , *COMBINATION drug therapy , *CONFIDENCE intervals , *SURVIVAL , *TUMOR classification , *RANDOMIZED controlled trials , *POSTMENOPAUSE , *TREATMENT duration , *THERAPEUTICS - Abstract
Abstract: Purpose: We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients. In addition, we analyse the prognostic and predictive value of centrally assessed subtypes. Methods: Postmenopausal patients with breast cancer and positive nodes, deep invasion or size exceeding 5cm were randomly assigned to 1year of tamoxifen, or cyclophosphamide 600mg/m2, methotrexate 40mg/m2 and fluorouracil 600mg/m2 intravenously on day 1 every 4weeks for nine cycles plus tamoxifen (CMFT). Tissue microarrays were constructed retrospectively and oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and proliferation-related Ki-67 antigen (Ki67) status were assessed. Results: From October 1982 through March 1990 we randomised 1445 patients and 969 (67%) were eligible for the biomarker analysis. At 10-years 936 women had suffered a disease-free survival (DFS) event (tamoxifen, 495 events in 686 patients; CMFT, 441 events in 642 patients). The addition of CMF to tamoxifen significantly improved DFS (adjusted hazard ratio 0.82; 95% confidence interval (CI) 0.71–0.93; P =0.003) but not overall survival (adjusted hazard ratio 0.95; 95% CI 0.85–1.08; P =0.44). DFS was superior in Luminal A tumours (ER or PgR positive, HER2 negative and Ki67 ⩽14%) when compared to Luminal B or non-luminal (ER and PgR negative) tumours. There was no statistical evidence of heterogeneity by subtype in the benefit from CMF (P interaction =0.45). Conclusion: CMF added to 1year of tamoxifen reduces the risk of a DFS event. The benefit from CMF was not significantly different in Luminal A and B subtypes. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
34. The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
- Author
-
Rosendahl, Mikkel, Ahlgren, Johan, Andersen, Jørn, Bergh, Jonas, Blomquist, Carl, Lidbrink, Elisabet, Lindman, Henrik, Mouridsen, Henning, Bjerre, Karsten, and Andersson, Michael
- Subjects
- *
CHEMOTHERAPY complications , *AMENORRHEA , *LEUCOCYTES , *AGE groups , *MENSTRUATION disorders , *CONFIDENCE intervals , *DRUG dosage , *DISEASE risk factors ,BREAST cancer chemotherapy - Abstract
Abstract: Study aim: Amenorrhoea is a common side-effect to chemotherapy of premenopausal women. We examine the association between chemotherapy-induced leucopaenia and the development of amenorrhoea in premenopausal women with breast cancer. Materials and methods: In a multi-centre, randomised, controlled study, 1016 premenopausal women received seven series of FEC (F: fluorouracil, E: epirubicin and C: cyclophosphamide) for early stage breast cancer. In the first series, all patients received standard dose (F: 600mg/m2, E: 60mg/m2 and C: 600mg/m2). Patients with leukocyte nadir 1.0–1.9×109/l continued with standard dose for the remaining six series (STANDARDREGISTERED, n =279). Patients with leukocyte nadir ⩾2×109/l were randomised to standard (STANDARDRANDOMISED, n =373) or increased (TAILORED, n =364) dose of E and C. After each series, leukocyte nadir was evaluated. Absent bleeding after the 5th–7th series of FEC was interpreted as amenorrhoea. Results: The risk of amenorrhoea increased with age. In age-stratified analysis of the STANDARD groups (equal dose, different initial leukocyte nadir) low leukocyte nadir was associated with amenorrhoea for patients in the age-group 25–39years (P =0.010). In age-stratified analysis in the randomised groups (different doses, same initial leukocyte nadir) a dose related increased risk of amenorrhoea was found for age-groups 25–39 (RR: 1.15, 95% confidence interval (CI): 1.06–1.24) and 40–44years (RR:1.21, 95% CI: 1.001–1.47). Conclusion: Age is the most important risk factor of amenorrhoea after FEC chemotherapy. However, for younger patients, lower leukocyte nadir in response to STANDARD FEC treatment or increased doses of C and E were associated with increased risk of amenorrhoea. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
35. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer.
- Author
-
Piccart-Gebhart, Martine J., Procter, Marion, Leyland-Jones, Brian, Goldhirsch, Aron, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Bell, Richard, Jackisch, Christian, Cameron, David, Dowsett, Mitch, Barrios, Carlos H., Steger, Günther, Huang, Chiun-Shen, Andersson, Michael, Inbar, Moshe, Lichinitser, Mikhail, Láng, István, and Nitz, Ulrike
- Subjects
- *
DRUG therapy , *CANCER treatment , *CANCER in women , *BREAST cancer , *THERAPEUTICS , *CLINICAL medicine , *DRUGS , *MEDICINE , *HEALTH , *WOMEN'S health - Abstract
Background: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. Methods: This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. Results: Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab. Conclusions: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.) N Engl J Med 2005;353:1659-72. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
36. Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy.
- Author
-
Overgaard, Marie, Hansen, Per S., Overgaard, Jens, Rose, Carsten, Andersson, Michael, Bach, Flemming, Kjaer, Mogens, Gadeberg, Carl C., Mouridsen, Henning T., Jensen, Maj-Britt, and Zedeler, Karin
- Subjects
- *
BREAST cancer , *IRRADIATION , *DRUG therapy , *MASTECTOMY , *PHARMACOLOGY , *LYMPH nodes , *CANCER invasiveness , *CANCER - Abstract
Background: Irradiation after mastectomy can reduce locoregional recurrences in women with breast cancer, but whether it prolongs survival remains controversial. We conducted a randomized trial of radiotherapy after mastectomy in high-risk premenopausal women, all of whom also received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF). Methods: A total of 1708 women who had undergone mastectomy for pathological stage II or III breast cancer were randomly assigned to receive eight cycles of CMF plus irradiation of the chest wall and regional lymph nodes (852 women) or nine cycles of CMF alone (856 women). The median length of follow-up was 114 months. The end points were locoregional recurrence, distant metastases, disease-free survival, and overall survival. Results: The frequency of locoregional recurrence alone or with distant metastases was 9 percent among the women who received radiotherapy plus CMF and 32 percent among those who received CMF alone (P<0.001). The probability of survival free of disease after 10 years was 48 percent among the women assigned to radiotherapy plus CMF and 34 percent among those treated only with CMF (P<0.001). Overall survival at 10 years was 54 percent among those given radiotherapy and CMF and 45 percent among those who received CMF alone (P<0.001). Multivariate analysis demonstrated that irradiation after mastectomy significantly improved disease-free survival and overall survival, irrespective of tumor size, the number of positive nodes, or the histopathological grade. Conclusions: The addition of postoperative irradiation to mastectomy and adjuvant chemotherapy reduces locoregional recurrences and prolongs survival in high-risk premenopausal women with breast cancer. (N Engl J Med 1997;337:949-55.) [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.